Dermatology Pathways
19 pathways
Work through 19 interactive dermatology decision pathways — branching, guideline-grounded workflows that take you from presentation to assessment, risk stratification and management. Each pathway cites its source (NICE, ESC, AHA and specialty guidance), embeds the relevant calculators, and makes escalation and safety-netting explicit. For decision support only — apply clinical judgement and local protocols.
- Suspicious Pigmented Lesion — Melanoma PathwayABCDE assessment, 2WW referral, and Breslow thickness staging for melanomaNICE NG14 2015 / BAD
- Cellulitis and ErysipelasEron class severity grading, IV vs oral antibiotic decision, and marking for monitoringNICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up TherapyPASI/DLQI-based severity classification and topical to biologic treatment escalation for plaque psoriasisNICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up TherapyIGA-based severity assessment and NICE step-up treatment ladder for atopic eczema in adults and childrenNICE NG95 2023
- Urticaria and AngioedemaAcute vs chronic urticaria classification, anaphylaxis exclusion, and antihistamine step-up managementBSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and TreatmentSeverity grading and NICE-aligned topical to systemic to isotretinoin treatment escalationNICE NG198 2021 / BAD
- Non-Melanoma Skin Cancer — BCC and SCCBCC vs SCC recognition, risk stratification, 2WW referral criteria, and treatment optionsNICE NG12 2015 / BAD NMSC Guidelines
- Stevens-Johnson Syndrome / TENSevere drug reaction — stop offending drug, ITU/burns unit, supportive care, SCORTEN prognosis, IVIG / ciclosporin in selected.BAD 2016; UK Dermatology
- ErythrodermaGeneralised erythema + scaling >90% body surface — recognise life-threatening complications, identify cause, supportive care.BAD; UK Dermatology
- Pemphigus / Bullous PemphigoidDistinguish (clinical + immunofluorescence) — pemphigus vulgaris (intra-epidermal, mucosal involvement) vs bullous pemphigoid (sub-epidermal, elderly), corticosteroid + steroid-sparing.BAD 2017
- Eczema HerpeticumHSV superinfection of eczematous skin — punched-out vesicles, monomorphic, fever, systemic illness; aciclovir IV.BAD; NICE CKS
- Drug Eruption / DRESSRange of drug eruptions — recognise red flag (DRESS, SJS/TEN, AGEP), stop drug, supportive care, organ monitoring in DRESS.BAD; UK Drug Allergy Network
- Hidradenitis SuppurativaHurley staging, lifestyle (smoking, weight), antibiotics, biologics, surgical excision for severe.BAD 2018; European S1
- VitiligoDiagnosis, autoimmune screen, narrowband UVB, topical / oral therapies, JAK inhibitors emerging, psychological support.BAD 2008 (under review); European S1
- Alopecia (Areata + Scarring)Distinguish patterns (alopecia areata, androgenetic, telogen effluvium, scarring), exclude reversible causes, biologics for severe AA.BAD; British Hair + Nail Society
- RosaceaSubtype-driven (erythematotelangiectatic, papulopustular, phymatous, ocular), trigger avoidance, topical + systemic therapies.BAD 2017; NICE CKS
- HyperhidrosisDistinguish primary (focal — axillae, palms, soles) from secondary (medical cause). Topical → iontophoresis → botox → systemic → surgery.BAD; NICE CKS
- PhotodermatosisDifferentiate idiopathic (PMLE, solar urticaria), drug-induced, autoimmune (lupus), genetic; sun avoidance + targeted therapy.BAD
- Cutaneous Lupus ErythematosusDistinguish ACLE (malar) / SCLE (annular) / CCLE (discoid) — biopsy + autoimmune workup, hydroxychloroquine + sun protection.BAD; EULAR